

REMARKS

I. Amendments

The title of the invention has been modified as requested by the Examiner.

A statement describing related patent applications has been added.

Claims 1 and 26 have been amended to specifically claim particular aspects of the invention, without prejudice to filing future continuing applications. Claims 2 and 12 have been amended to remove excess brackets from the claims.

Support for the amendments is found in the claims and specification as originally filed.

II. Objection to Claims 1-28

Applicants have limited Claim 1 to recite to specific amino acid peptides having the amino acid sequence of SEQ ID NO: 3-21, 25 and 28-40.

This objection has been overcome by the amendment.

II. Rejection of Claims 26-28 under §112 first paragraph - enablement

Claims 26, 27 and 28 are ultimately dependent upon Claim 1, which has now been amended to limit the scope of the claim to peptides having a particular amino acid sequence. Claim 26 has been amended to clearly recite the pharmaceutical composition.

In view of the amendments to the Claims, the Examiner's rejection should be withdrawn.

III. Rejection of Claims 26-28 under §112 first paragraph - written description

Claims 26, 27 and 28 are ultimately dependent upon Claim 1, which has now been amended to limit the scope of the claim to peptides having a particular amino acid sequence.

In view of the amendment to Claim 1, the Examiner's rejection should be withdrawn.

IV. Conclusion

Applicants request that a corrected Filing Receipt be issued upon allowance of the claims, showing the correct date for the priority document.


Reconsideration of the claims as amended in view of the traverse made above is solicited. Early allowance of the claims is requested. Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call applicants' attorney.

Dated:

4/21/03

(847)383-3372
(847)383-3391

Respectfully submitted,



Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA